2026-10-13T02:58:51Z https://api.figshare.com/v2/oai

oai:figshare.com:article/34047237 2026-10-01T17:04:25Z category_7 category_15 category_16 category_19 category_21 category_24 category_135 portal_87 item_type_6 month_year_10_2026

Current clinical practice of Botulinum toxin A treatment in the lower extremities in children with cerebral palsy in Sweden – a population-based registry study Gunnar Hägglund (62333) Ann I. Alriksson-Schmidt (8579367) Medicine Neuroscience Physiology Pharmacology Biotechnology Evolutionary Biology Computational Biology Age botulinum toxin a cerebral palsy CPUP GMFCS level registry study spasticity <p>To describe current lower-extremity Botulinum toxin A (BTX-A) treatment in children with cerebral palsy (CP) in Sweden and compare treatment patterns in 2023–2024 with published nationwide data from 2014–2015.</p> <p>This retrospective registry study included 3,216 children aged 1–15 years registered in the Swedish CP follow-up program and national quality registry (CPUP) in 2023–2024. BTX-A treatment was analyzed in relation to age, sex, Gross Motor Function Classification System (GMFCS) level, CP subtype, and injected muscle groups. Logistic regression and chi-square tests were used.</p> <p>BTX-A treatment of the lower extremities was reported for 828 children (26%). Treatment was most common at 7–9 years of age (33%) and among children at GMFCS levels III (38%) and IV (40%). Bilateral spastic CP had the highest treatment rate among CP subtypes (39%). The gastrocnemius–soleus was the most frequently treated muscle group (75% of treated children). The overall proportion treated was identical to that reported for 3,028 children in 2014–2015 (26%), but treatment in 2023–2024 was relatively more common in older children and at higher GMFCS levels.</p> <p>BTX-A remains an established component of lower-extremity spasticity management in Swedish children with CP. Treatment patterns have shifted slightly toward older children and those with more severe motor impairment, while the gastrocnemius–soleus remains the primary target muscle group. These findings may help rehabilitation teams anticipate treatment needs and coordinate BTX-A with other components of individualized rehabilitation.</p> 2026-10-01T17:04:25Z Text Journal contribution 10.6084/m9.figshare.34047237.v1 https://figshare.com/articles/journal_contribution/Current_clinical_practice_of_Botulinum_toxin_A_treatment_in_the_lower_extremities_in_children_with_cerebral_palsy_in_Sweden_a_population-based_registry_study/34047237 CC BY 4.0